1. Home
  2. ANNX vs SMID Comparison

ANNX vs SMID Comparison

Compare ANNX & SMID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • SMID
  • Stock Information
  • Founded
  • ANNX 2011
  • SMID 1960
  • Country
  • ANNX United States
  • SMID United States
  • Employees
  • ANNX N/A
  • SMID N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • SMID Building Materials
  • Sector
  • ANNX Health Care
  • SMID Industrials
  • Exchange
  • ANNX Nasdaq
  • SMID Nasdaq
  • Market Cap
  • ANNX 253.8M
  • SMID 206.7M
  • IPO Year
  • ANNX 2020
  • SMID 1995
  • Fundamental
  • Price
  • ANNX $3.09
  • SMID $35.20
  • Analyst Decision
  • ANNX Strong Buy
  • SMID
  • Analyst Count
  • ANNX 4
  • SMID 0
  • Target Price
  • ANNX $13.00
  • SMID N/A
  • AVG Volume (30 Days)
  • ANNX 2.4M
  • SMID 11.1K
  • Earning Date
  • ANNX 11-13-2025
  • SMID 08-14-2025
  • Dividend Yield
  • ANNX N/A
  • SMID N/A
  • EPS Growth
  • ANNX N/A
  • SMID 162.25
  • EPS
  • ANNX N/A
  • SMID 2.27
  • Revenue
  • ANNX N/A
  • SMID $90,998,000.00
  • Revenue This Year
  • ANNX N/A
  • SMID N/A
  • Revenue Next Year
  • ANNX N/A
  • SMID N/A
  • P/E Ratio
  • ANNX N/A
  • SMID $15.70
  • Revenue Growth
  • ANNX N/A
  • SMID 32.97
  • 52 Week Low
  • ANNX $1.29
  • SMID $25.13
  • 52 Week High
  • ANNX $7.85
  • SMID $51.96
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 60.42
  • SMID 38.59
  • Support Level
  • ANNX $2.91
  • SMID $35.16
  • Resistance Level
  • ANNX $3.38
  • SMID $36.70
  • Average True Range (ATR)
  • ANNX 0.24
  • SMID 2.11
  • MACD
  • ANNX 0.02
  • SMID -0.31
  • Stochastic Oscillator
  • ANNX 61.87
  • SMID 14.01

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

Share on Social Networks: